Aesica Pharmaceuticals, a contract development and manufacturing organization, has relocated its development and clinical manufacturing services from Nottingham to Queenborough, United Kingdom. As a consequence, Aesica now intends to provide full manufacturing and development services at its Queenborough site with the addition of a new development center. From Queenborough, the company now provides active pharmaceutical ingredient (API) production, formulation development and clinical manufacture through to commercial-scale product manufacturing.

The new development center will focus on the development of solid and liquid dosage forms, including the ability to manufacture clinical drug product for Phase I to Phase III studies. As the new center sits on a commercial site, the technical transfer from development to commercial will be a smooth transition. The development center will be able to handle potent and controlled drugs that mirror the commercial offering from Queenborough. The pharmaceutical contract manufacturer will also still offer semi-solid development. Furthermore, inhalation services will continue with access to technology and know-how, including metered-dose inhalers (MDI), dry-powder inhalers being provided by Bespak within the Consort Medical Group. Asecia and Bespak are two subsidiaries of Consort Medical Group. 

The new development center at Queenborough has more than twice the capacity of the existing one in Nottingham and consequently provides scope for further business expansion.

Source: Aesica Pharmaceuticals